Do patients need to take Resmetirom for life?

Resmetirom-Rezdiffra is a selective thyroid hormone receptor beta (THR-β) agonist, mainly used to improve liver lipid deposition and metabolic function in adult patients with non-alcoholic steatohepatitis (NASH) and related liver fibrosis. There is no fixed clinical answer as to whether lifelong use is required, because its use strategy needs to be individually adjusted based on the patient's disease progression, efficacy response, and long-term tolerance. The core function of rismetirol is to activate THR-β receptors in the liver, promote lipid metabolism and reduce liver fat content, thereby improving the inflammatory response and delaying the process of fibrosis. This effect is reversible, and hepatic lipid deposition may gradually increase once the drug is discontinued, thus requiring continued medication in some patients to maintain therapeutic effects.

In clinical studies, multi-cycle use of resmetirol has been shown to stabilize or improve liver fibrosis indicators and improve liver function-related laboratory indicators. However, sinceNASH is a chronic metabolic disease, its pathological process exists for a long time and is closely related to lifestyle, weight management and metabolic status. Therefore, resmetirol is viewed more as a long-term management tool rather than a one-time cure. In actual treatment, doctors usually judge whether to continue maintenance treatment or adjust the dose based on the patient's imaging evaluation, liver biochemical indicators, and fibrosis score.

In addition, the long-term safety of resmetirol is also an important factor in deciding whether to continue using the drug. Potential risks such as hepatotoxicity, gallbladder-related events, and interactions with statins require patients to undergo regular follow-up and laboratory monitoring during treatment to ensure the safety of long-term use. For some patients whose symptoms are stable and their lifestyle is effectively controlled, physicians may consider intermittent courses of treatment or periodic discontinuation of medication, but this requires rigorous clinical evaluation and risk management.

Reference materials:https://www.drugs.com/monograph/resmetirom.html